Literature DB >> 8320265

Regulated expression of exon v6 containing isoforms of CD44 in man: downregulation during malignant transformation of tumors of squamocellular origin.

M Salmi1, K Grön-Virta, P Sointu, R Grenman, H Kalimo, S Jalkanen.   

Abstract

CD44 is a family of glycoproteins involved in cell-cell and cell-matrix interactions. In addition to the major 90-kD form present on most hematopoietic cells, larger 140-230 kD forms are found on keratinocytes and carcinoma cell lines. These bigger isoforms of CD44 arise by alternative splicing that results in insertion of one or more of the "variant" exons into the extracellular part of the 90-kD constant form of the molecule. In rat, v6 (variant exon v6) containing form of CD44 confers metastatic potential to carcinoma cells, and therefore, it is of interest to study the distribution of this isoform in humans. We raised antibodies against a synthetic peptide containing a sequence encoded by the exon v6. A mAb thus obtained (designated Var3.1) strongly reacted with the plasma membranes of squamous cells in upper layers of skin and tonsil surface epithelia. Weaker staining was seen in germinal centers, vascular endothelia and enterocytes. Exon v6 containing forms of CD44 (CD44v6) were absent from tissue leukocytes and connective tissue components. In comparison, Hermes-3 epitope (on the constant part) containing forms of CD44 were preferentially localized in basal layers of epithelia, present on the surface on most leukocytes and connective tissue cells, and undetectable on the luminal surface of high endothelial venules. In benign neoplasms, epithelial cells stained with mAb Var3.1 like in normal tissues. In contrast, immunostaining of 30 squamous carcinoma specimens (both primary and metastatic lesions) revealed that malignant transformation resulted in downregulation or disappearance of Var3.1 epitope, but in majority of cases, not in diminished synthesis of the Hermes-3 epitope. Biochemical analyses showed that mAb Var3.1 recognized two major forms of CD44 (220 and 300 kD). In conclusion, epitopes on exon v6 and constant part of CD44 are differentially synthesized and regulated during normal and malignant growth of cells in man.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8320265      PMCID: PMC2119652          DOI: 10.1083/jcb.122.2.431

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  54 in total

1.  Identification and characterization of a cell surface proteoglycan on keratinocytes.

Authors:  J G Haggerty; R H Bretton; L M Milstone
Journal:  J Invest Dermatol       Date:  1992-10       Impact factor: 8.551

2.  Multiple variants of the human lymphocyte homing receptor CD44 generated by insertions at a single site in the extracellular domain.

Authors:  D G Jackson; J Buckley; J I Bell
Journal:  J Biol Chem       Date:  1992-03-05       Impact factor: 5.157

Review 3.  The transmembrane hyaluronate receptor (CD44): multiple functions, multiple forms.

Authors:  B F Haynes; H X Liao; K L Patton
Journal:  Cancer Cells       Date:  1991-09

4.  Lymphocyte homing and clinical behavior of non-Hodgkin's lymphoma.

Authors:  S Jalkanen; H Joensuu; K O Söderström; P Klemi
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

5.  Significance of CD44 gene products for cancer diagnosis and disease evaluation.

Authors:  Y Matsumura; D Tarin
Journal:  Lancet       Date:  1992-10-31       Impact factor: 79.321

6.  T-cell-receptor-independent activation of cytolytic activity of cytotoxic T lymphocytes mediated through CD44 and gp90MEL-14.

Authors:  A Seth; L Gote; M Nagarkatti; P S Nagarkatti
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

7.  Participation in normal immune responses of a metastasis-inducing splice variant of CD44.

Authors:  R Arch; K Wirth; M Hofmann; H Ponta; S Matzku; P Herrlich; M Zöller
Journal:  Science       Date:  1992-07-31       Impact factor: 47.728

8.  Human T cell activation by OKT3 is inhibited by a monoclonal antibody to CD44.

Authors:  B L Rothman; M L Blue; K A Kelley; D Wunderlich; D V Mierz; T M Aune
Journal:  J Immunol       Date:  1991-10-15       Impact factor: 5.422

9.  Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin.

Authors:  S Jalkanen; M Jalkanen
Journal:  J Cell Biol       Date:  1992-02       Impact factor: 10.539

10.  Distinct effects of two CD44 isoforms on tumor growth in vivo.

Authors:  M S Sy; Y J Guo; I Stamenkovic
Journal:  J Exp Med       Date:  1991-10-01       Impact factor: 14.307

View more
  34 in total

1.  CD44 variant exons in leukemia and lymphoma.

Authors:  Elif Akisik; Sevil Bavbek; Nejat Dalay
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

2.  Expression of adhesion molecule CD44 on human corneas.

Authors:  S N Zhu; B Nölle; G Duncker
Journal:  Br J Ophthalmol       Date:  1997-01       Impact factor: 4.638

3.  Differential expression of CD44(S) and variant isoforms v3, v10 in three-dimensional cultures of mouse melanoma cell lines.

Authors:  Anjali Shiras; Arti Bhosale; Anjali Patekar; Varsha Shepal; Padma Shastry
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

4.  Human vascular adhesion protein-1 in smooth muscle cells.

Authors:  K Jaakkola; K Kaunismäki; S Tohka; G Yegutkin; E Vänttinen; T Havia; L J Pelliniemi; M Virolainen; S Jalkanen; M Salmi
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 5.  The normal structure and function of CD44 and its role in neoplasia.

Authors:  R J Sneath; D C Mangham
Journal:  Mol Pathol       Date:  1998-08

6.  CD44 isoform expression follows two alternative splicing pathways in breast tissue.

Authors:  X Roca; J L Mate; A Ariza; A M Muñoz-Mármol; C von Uexküll-Güldeband; I Pellicer; J J Navas-Palacios; M Isamat
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

Review 7.  The clinical significance of malfunction of the CD44 locus in malignancy.

Authors:  D Tarin; J Bolodeoku; S J Hatfill; T Sugino; A C Woodman; K Yoshida
Journal:  J Neurooncol       Date:  1995-12       Impact factor: 4.130

Review 8.  Expression of the CD44 adhesion molecule in tumours of the central and peripheral nervous system.

Authors:  G H Baltuch; N de Tribolet; E G Van Meir
Journal:  J Neurooncol       Date:  1995-12       Impact factor: 4.130

9.  CD44 standard and variant isoform expression in normal human skin appendages and epidermis.

Authors:  W K Seelentag; U Günthert; P Saremaslani; E Futo; M Pfaltz; P U Heitz; J Roth
Journal:  Histochem Cell Biol       Date:  1996-09       Impact factor: 4.304

Review 10.  The regulation of splice-site selection, and its role in human disease.

Authors:  T A Cooper; W Mattox
Journal:  Am J Hum Genet       Date:  1997-08       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.